Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents
Shuang Xu, Shadisadat Esmaeili, E Fabian Cardozo-Ojeda, Ashish Goyal, Judith M White, Stephen J Polyak, Joshua T Schiffer
Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01015-23
Existing pharmacodynamic (PD) mathematical models for drug combina tions discriminate antagonistic, additive, multiplicative, and synergistic effects, but fail to consider how concentration-dependent drug interaction effects may vary across an entire dose-response matrix. We developed a two-way pharmacodynamic (TWPD) model to capture the PD of two-drug combinations. TWPD captures interactions between upstream and downstream drugs that act on different stages of viral replication, by quantifying upstream drug efficacy and concentration-dependent effects on down stream drug pharmacodynamic parameters. We applied TWPD to previously published in vitro drug matrixes for repurposed potential anti-Ebola and anti-SARS-CoV-2 drug pairs. Depending on the drug pairing, the model recapitulated combined efficacies as or more accurately than existing models and can be used to infer efficacy at untested drug concentrations. TWPD fits the data slightly better in one direction for all drug pairs, meaning that we can tentatively infer the upstream drug. Based on its high accuracy, TWPD could be used in concert with PK models to estimate the therapeutic effects of drug pairs in vivo.
AUTHOR CONTRIBUTIONS Shuang
ADDITIONAL FILES The following material is available online.
Supplemental Material Supplemental material (AAC01015-23-s0001.docx). Figures S1 to S7; Tables S1 to S10 .
References
Andersen, Ianevski, Lysvand, Vitkauskiene, Oksenych et al., Discovery and development of safe-in-man broad-spectrum antiviral agents, Int J Infect Dis,
doi:10.1093/infdis/jiy304Berenbaum, What is synergy?, Pharmacol Rev
Bobrowski, Chen, Eastman, Itkin, Shinn et al., Synergistic and antagonistic drug combinations against SARS-CoV-2, Mol Ther,
doi:10.1016/j.csbj.2015.09.001Brun, Dennis, Greco, Bernacki, Pera et al., Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm, Antimicrob Agents Chemother,
doi:10.1128/AAC.01007-06Bulitta, Landersdorfer, Forrest, Brown, Neely et al., Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients, Curr Pharm Biotechnol,
doi:10.1080/19466315.2018.1437071Bösl, Ianevski, Than, Andersen, Kuivanen et al., Common nodes of virus-host interaction revealed through an integrated network analysis, Front Immunol,
doi:10.1016/j.csbj.2015.09.001Chaudhuri, Symons, Deval, Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond, Antiviral Res,
doi:10.1093/infdis/jiy304Cheng, Williamson, Zheng, Improving therapy of severe infections through drug repurposing of synergistic combinations, Curr Opin Pharmacol,
doi:10.1016/j.csbj.2015.09.001De Mello, Tao, Kim, Bulitta, Rodriquez et al., Zika virus replication is substantially inhibited by novel favipiravir and interferon alpha combination regimens, Antimicrob Agents Chemother,
doi:10.1016/j.csbj.2015.09.001Degregorio, Wurz, Taras, Erkkola, Halonen et al., Pharmacokinetics of (deaminohydroxy) toremifene in humans: a new, selective estrogen-receptor modulator, Eur J Clin Pharmacol,
doi:10.1007/s002280000176Drusano, Argenio, Preston, Barone, Symonds et al., Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir, Antimicrob Agents Chemother,
doi:10.1128/AAC.44.6.1655-1659.2000Drusano, Neely, Van Guilder, Schumitzky, Brown et al., Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculo sis, PLoS One,
doi:10.1371/journal.pone.0101311Dyall, Nelson, Dewald, Guha, Hart et al., Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures, J Infect Dis,
doi:10.1093/infdis/jiy304Esmaeili, Owens, Wagoner, Polyak, Schiffer, A unifying model to explain nirmatrelvir / ritonavir's high efficacy during early treatment and low efficacy as post-exposure prophylaxis, and to predict viral rebound, medRxiv,
doi:10.1101/2023.08.23.23294505Finch, Dyall, Xu, Nelson, Postnikova et al., Formulation, stability, pharmacokinetic, and modeling studies for tests of synergistic combinations of orally available approved drugs against Ebola virus in vivo, Microorganisms,
doi:10.3390/microorganisms9030566Finch, Dyall, Xu, Nelson, Postnikova et al., Formulation, stability, pharmacokinetic, and modeling studies for tests of synergistic combinations of orally available approved drugs against Ebola virus in vivo, Microorganisms,
doi:10.3390/microorganisms9030566Foucquier, Guedj, Analysis of drug combinations: current methodological landscape, Pharmacol Res Perspect,
doi:10.1002/prp2.149Franco, Tao, Hanrahan, Zhou, Bulitta et al., Combination regimens of favipiravir plus interferon alpha inhibit chikungunya virus replication in clinically relevant human cell lines, Microorganisms,
doi:10.3390/microorganisms9020307Haffizulla, Hartman, Hoppers, Resnick, Samudrala et al., Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial, Lancet Infect Dis,
doi:10.1016/S1473-3099(14)70717-0Hakamaki, Apoil, Arstila, Timmer, Lehtonen, Bepridil in the elderly. A pharmacokinetic and clinical monitoring study, Curr Ther Res
Herring, Oda, Wagoner, Kirchmeier, Connor et al., Inhibition of arenaviruses by combinations of orally available approved drugs, Antimicrob Agents Chemother,
doi:10.1016/j.csbj.2015.09.001Hulseberg, Fénéant, Wijs, Kessler, Nelson et al., Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses, J Virol,
doi:10.1128/JVI.02185-18Humeniuk, Mathias, Cao, Osinusi, Shen et al., Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects, Clin Transl Sci,
doi:10.1111/cts.12840Ianevski, Giri, Aittokallio, SynergyFinder 2.0: visual analytics of multi-drug combination synergies, Nucleic Acids Res,
doi:10.1016/j.csbj.2015.09.001Ianevski, Giri, Aittokallio, SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples, Nucleic Acids Res,
doi:10.1016/j.csbj.2015.09.001Ianevski, He, Aittokallio, Tang, SynergyFinder: a web application for analyzing drug combination dose-response matrix data, Bioinformatics,
doi:10.1016/j.csbj.2015.09.001Jilek, Zarr, Sampah, Rabi, Bullen et al., A quantitative basis for antiretroviral therapy for HIV-1 infection, Nat Med,
doi:10.1038/nm.2649Johansen, Brannan, Delos, Shoemaker, Stossel et al., FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection, Sci Transl Med,
doi:10.1126/scitranslmed.3005471Johansen, Dewald, Shoemaker, Hoffstrom, Lear-Rooney et al., A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity, Sci Transl Med,
doi:10.1126/scitranslmed.aaa5597Joshua, Swan, Corey, Ossig, Ruebsamen-Schaeff et al., Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes, Sci Transl Med,
doi:10.1126/scitranslmed.aad6654Landersdorfer, Ly, Xu, Tsuji, Bulitta, Quantifying subpopulation synergy for antibiotic combinations via mechanismbased modeling and a sequential dosing design, Antimicrob Agents Chemother,
doi:10.1080/19466315.2018.1437071Liu, Yin, Languino, Altieri, Evaluation of drug combina tion effect using a bliss independence dose-response surface model, Stat Biopharm Res
Lo, Jordan, Arvey, Sudhamsu, Shrivastava-Ranjan et al., GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses, Sci Rep,
doi:10.1038/srep43395Loewe, The problem of synergism and antagonism of combined drugs, Arzneim-Forsch
Pizzorno, Padey, Dubois, Julien, Traversier et al., In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2, Antiviral Res,
doi:10.1016/j.csbj.2015.09.001Pizzorno, Padey, Terrier, Rosa-Calatrava, Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy, Front Immunol,
doi:10.3389/fimmu.2019.00531Pomeroy, Drusano, Rodriquez, Brown, Searching for synergy: identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system, Antiviral Res,
doi:10.1016/j.antiviral.2017.09.001Prichard, Aseltine, Shipman, MacSynergyTM II
Pécheur, Borisevich, Halfmann, Morrey, Smee et al., The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses, J Virol,
doi:10.1128/JVI.02077-15Reeves, Mayer, Decamp, Huang, Zhang et al., High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the antibody mediated prevention trials, Nat Commun,
doi:10.1038/s41467-023-43384-yRonfeld, Tremaine, Wilner, Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers, Clin Pharmacokinet,
doi:10.2165/00003088-199700321-00004Santos Nascimento, De Aquino, Da, Ef, Drug repurposing: a strategy for discovering inhibitors against emerging viral infections, Curr Med Chem,
doi:10.1016/j.csbj.2015.09.001Schiffer, Swan, Corey, Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents, Antimicrob Agents Chemother,
doi:10.1128/AAC.01114-13Sheahan, Sims, Graham, Menachery, Gralinski et al., Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med,
doi:10.1126/scitranslmed.aal3653Snyder, Argenio, Weislow, Bilello, Drusano, The triple combination indinavir-zidovudine-lamivudine is highly synergistic, Antimicrob Agents Chemother,
doi:10.1128/AAC.44.4.1051-1058.2000Snyder, Goebel, Koide, Ptak, Kalkeri, Synergistic antiviral activity of Sofosbuvir and type-I interferons (α and β) against Zika virus, J Med Virol,
doi:10.1016/j.csbj.2015.09.001Sun, He, Martínez-Romero, Kouznetsova, Tawa et al., Synergistic drug combination effectively blocks Ebola virus infection, Antiviral Res,
doi:10.1016/j.csbj.2015.09.001Sun, He, Qiu, Zhu, Zhao et al., Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers, Int J Clin Pharmacol Ther,
doi:10.5414/CP201843Wagoner, Herring, Hsiang, Ianevski, Biering et al., Combinations of host-and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2, Microbiol Spectr,
doi:10.1016/j.csbj.2015.09.001Warren, Jordan, Lo, Ray, Mackman et al., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature,
doi:10.1038/nature17180Wicha, Chen, Clewe, Simonsson, A general pharmaco dynamic interaction model identifies perpetrators and victims in drug interactions, Nat Commun,
doi:10.1038/s41467-017-01929-yWicha, Kees, Kuss, Kloft, Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus, Pharm Res,
doi:10.1007/s11095-015-1632-3Yadav, Landersdorfer, Nation, Boyce, Bulitta, Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii, Antimicrob Agents Chemother,
doi:10.1128/AAC.04379-14Yadav, Wennerberg, Aittokallio, Tang, Searching for drug synergy in complex dose-response landscapes using an interaction potency model, Comput Struct Biotechnol J,
doi:10.1016/j.csbj.2015.09.001Zheng, Sun, Simeonov, Drug repurposing screens and synergistic drug-combinations for infectious diseases, Br J Pharmacol
{ 'indexed': {'date-parts': [[2024, 4, 4]], 'date-time': '2024-04-04T00:48:57Z', 'timestamp': 1712191737855},
'reference-count': 67,
'publisher': 'American Society for Microbiology',
'issue': '4',
'license': [ { 'start': { 'date-parts': [[2024, 4, 3]],
'date-time': '2024-04-03T00:00:00Z',
'timestamp': 1712102400000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'},
{ 'start': { 'date-parts': [[2024, 4, 3]],
'date-time': '2024-04-03T00:00:00Z',
'timestamp': 1712102400000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://journals.asm.org/non-commercial-tdm-license'}],
'funder': [ {'name': 'HHS | National Institutes of Health', 'award': ['1 R01 AI178604-01']},
{'name': 'HHS | National Institutes of Health', 'award': ['1R01AI177512-01']}],
'content-domain': {'domain': ['journals.asm.org'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 4, 3]]},
'abstract': '<jats:title>ABSTRACT</jats:title>\n'
' <jats:sec>\n'
' <jats:title />\n'
' <jats:p>\n'
' Existing pharmacodynamic (PD) mathematical models for drug combinations '
'discriminate antagonistic, additive, multiplicative, and synergistic effects, but fail to '
'consider how concentration-dependent drug interaction effects may vary across an entire '
'dose-response matrix. We developed a two-way pharmacodynamic (TWPD) model to capture the PD '
'of two-drug combinations. TWPD captures interactions between upstream and downstream drugs '
'that act on different stages of viral replication, by quantifying upstream drug efficacy and '
'concentration-dependent effects on downstream drug pharmacodynamic parameters. We applied '
'TWPD to previously published\n'
' <jats:italic>in vitro</jats:italic>\n'
' drug matrixes for repurposed potential anti-Ebola and anti-SARS-CoV-2 drug '
'pairs. Depending on the drug pairing, the model recapitulated combined efficacies as or more '
'accurately than existing models and can be used to infer efficacy at untested drug '
'concentrations. TWPD fits the data slightly better in one direction for all drug pairs, '
'meaning that we can tentatively infer the upstream drug. Based on its high accuracy, TWPD '
'could be used in concert with PK models to estimate the therapeutic effects of drug pairs\n'
' <jats:italic>in vivo</jats:italic>\n'
' .\n'
' </jats:p>\n'
' </jats:sec>',
'DOI': '10.1128/aac.01015-23',
'type': 'journal-article',
'created': {'date-parts': [[2024, 3, 12]], 'date-time': '2024-03-12T13:01:08Z', 'timestamp': 1710248468000},
'update-policy': 'http://dx.doi.org/10.1128/asmj-crossmark-policy-page',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed '
'Ebola and SARS-CoV-2 agents',
'prefix': '10.1128',
'volume': '68',
'author': [ { 'given': 'Shuang',
'family': 'Xu',
'sequence': 'first',
'affiliation': [ { 'name': 'Fred Hutchinson Cancer Research Center, Vaccine and Infectious '
'Diseases Division, Seattle, Washington, USA'}]},
{ 'given': 'Shadisadat',
'family': 'Esmaeili',
'sequence': 'additional',
'affiliation': [ { 'name': 'Fred Hutchinson Cancer Research Center, Vaccine and Infectious '
'Diseases Division, Seattle, Washington, USA'}]},
{ 'given': 'E. Fabian',
'family': 'Cardozo-Ojeda',
'sequence': 'additional',
'affiliation': [ { 'name': 'Fred Hutchinson Cancer Research Center, Vaccine and Infectious '
'Diseases Division, Seattle, Washington, USA'}]},
{ 'given': 'Ashish',
'family': 'Goyal',
'sequence': 'additional',
'affiliation': [ { 'name': 'Fred Hutchinson Cancer Research Center, Vaccine and Infectious '
'Diseases Division, Seattle, Washington, USA'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-0532-996X',
'authenticated-orcid': True,
'given': 'Judith M.',
'family': 'White',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Microbiology, University of Virginia, '
'Charlottesville, Virginia, USA'},
{ 'name': 'Department of Cell Biology, University of Virginia, '
'Charlottesville, Virginia, USA'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-7475-9827',
'authenticated-orcid': True,
'given': 'Stephen J.',
'family': 'Polyak',
'sequence': 'additional',
'affiliation': [ { 'name': 'Virology Division, Department of Laboratory Medicine and '
'Pathology, University of Washington, Seattle, Washington, USA'},
{ 'name': 'Department of Global Health, University of Washington, Seattle, '
'Washington, USA'},
{ 'name': 'Department of Microbiology, University of Washington, Seattle, '
'Washington, USA'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-2598-1621',
'authenticated-orcid': True,
'given': 'Joshua T.',
'family': 'Schiffer',
'sequence': 'additional',
'affiliation': [ { 'name': 'Fred Hutchinson Cancer Research Center, Vaccine and Infectious '
'Diseases Division, Seattle, Washington, USA'},
{ 'name': 'Division of Allergy and Infectious Diseases, University of '
'Washington, Seattle, Washington, USA'}]}],
'member': '235',
'reference': [ { 'key': 'e_1_3_2_2_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2018.05.005'},
{'key': 'e_1_3_2_3_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.02.018'},
{ 'key': 'e_1_3_2_4_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.drudis.2019.04.006'},
{'key': 'e_1_3_2_5_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiy304'},
{'key': 'e_1_3_2_6_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2019.00531'},
{'key': 'e_1_3_2_7_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/prp2.149'},
{ 'key': 'e_1_3_2_8_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.drudis.2016.05.015'},
{'key': 'e_1_3_2_9_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bph.13895'},
{'key': 'e_1_3_2_10_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2019.02186'},
{'key': 'e_1_3_2_11_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.coph.2019.07.006'},
{ 'key': 'e_1_3_2_12_2',
'doi-asserted-by': 'publisher',
'DOI': '10.2174/0929867327666200812215852'},
{'key': 'e_1_3_2_13_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.01983-17'},
{'key': 'e_1_3_2_14_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.24932'},
{'key': 'e_1_3_2_15_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.01146-20'},
{ 'key': 'e_1_3_2_16_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2016.11.017'},
{ 'key': 'e_1_3_2_17_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ymthe.2020.12.016'},
{ 'key': 'e_1_3_2_18_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2020.104878'},
{'key': 'e_1_3_2_19_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v12101178'},
{'key': 'e_1_3_2_20_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/spectrum.03331-22'},
{'key': 'e_1_3_2_21_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/gkaa216'},
{ 'key': 'e_1_3_2_22_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/bioinformatics/btx162'},
{'key': 'e_1_3_2_23_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/gkac382'},
{ 'key': 'e_1_3_2_24_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/0166-3542(90)90001-n'},
{ 'key': 'e_1_3_2_25_2',
'volume-title': 'MacSynergyTM II',
'author': 'Prichard M',
'year': '1992',
'unstructured': 'Prichard M, Aseltine K, Shipman JC. 1992. MacSynergyTM II. University of '
'Michigan, Ann Arbor.'},
{ 'key': 'e_1_3_2_26_2',
'first-page': '93',
'article-title': 'What is synergy?',
'volume': '41',
'author': 'Berenbaum MC',
'year': '1989',
'unstructured': 'Berenbaum MC. 1989. What is synergy? Pharmacol Rev 41:93–141.',
'journal-title': 'Pharmacol Rev'},
{ 'key': 'e_1_3_2_27_2',
'first-page': '285',
'article-title': 'The problem of synergism and antagonism of combined drugs',
'volume': '3',
'author': 'Loewe S',
'year': '1953',
'unstructured': 'Loewe S. 1953. The problem of synergism and antagonism of combined '
'drugs. Arzneim-Forsch 3:285–290.',
'journal-title': 'Arzneim-Forsch'},
{ 'key': 'e_1_3_2_28_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1111/j.1744-7348.1939.tb06990.x'},
{'key': 'e_1_3_2_29_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.csbj.2015.09.001'},
{'key': 'e_1_3_2_30_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nm.2649'},
{'key': 'e_1_3_2_31_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-017-01929-y'},
{'key': 'e_1_3_2_32_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1023/a:1011907920641'},
{ 'key': 'e_1_3_2_33_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.drudis.2008.01.003'},
{'key': 'e_1_3_2_34_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3349/ymj.2017.58.1.1'},
{ 'key': 'e_1_3_2_35_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/03602532.2020.1726944'},
{ 'key': 'e_1_3_2_36_2',
'first-page': '331',
'article-title': 'The search for synergy: a critical review from a response surface '
'perspective',
'volume': '47',
'author': 'Greco WR',
'year': '1995',
'unstructured': 'Greco WR, Bravo G, Parsons JC. 1995. The search for synergy: a critical '
'review from a response surface perspective. Pharmacol Rev 47:331–385.',
'journal-title': 'Pharmacol Rev'},
{ 'key': 'e_1_3_2_37_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1128/AAC.44.4.1051-1058.2000'},
{ 'key': 'e_1_3_2_38_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1128/AAC.44.6.1655-1659.2000'},
{'key': 'e_1_3_2_39_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.01007-06'},
{'key': 'e_1_3_2_40_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11095-015-1632-3'},
{ 'key': 'e_1_3_2_41_2',
'volume-title': 'Empirical model-building and response surfaces',
'author': 'Box GE',
'year': '1987',
'unstructured': 'Box GE, Draper NR. 1987. Empirical model-building and response surfaces. '
'John Wiley & Sons.'},
{ 'key': 'e_1_3_2_42_2',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/microorganisms9030566'},
{'key': 'e_1_3_2_43_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.04379-14'},
{'key': 'e_1_3_2_44_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.00092-13'},
{'key': 'e_1_3_2_45_2', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/138920111798808428'},
{ 'key': 'e_1_3_2_46_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/19466315.2018.1437071'},
{ 'key': 'e_1_3_2_47_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/scitranslmed.3005471'},
{ 'key': 'e_1_3_2_48_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/scitranslmed.aaa5597'},
{'key': 'e_1_3_2_49_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.02077-15'},
{'key': 'e_1_3_2_50_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.02185-18'},
{'key': 'e_1_3_2_51_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nature17180'},
{'key': 'e_1_3_2_52_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep43395'},
{ 'key': 'e_1_3_2_53_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/scitranslmed.aal3653'},
{ 'key': 'e_1_3_2_54_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2014.07.014'},
{ 'key': 'e_1_3_2_55_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0101311'},
{ 'key': 'e_1_3_2_56_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2017.09.001'},
{ 'key': 'e_1_3_2_57_2',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/microorganisms9020307'},
{ 'key': 'e_1_3_2_58_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/scitranslmed.aad6654'},
{'key': 'e_1_3_2_59_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-023-43384-y'},
{ 'key': 'e_1_3_2_60_2',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/microorganisms9030566'},
{'key': 'e_1_3_2_61_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.01114-13'},
{ 'key': 'e_1_3_2_62_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2023.08.23.23294505'},
{ 'key': 'e_1_3_2_63_2',
'first-page': '752',
'article-title': 'Bepridil in the elderly. A pharmacokinetic and clinical monitoring '
'study',
'volume': '44',
'author': 'Hakamaki T',
'year': '1988',
'unstructured': 'Hakamaki T, Apoil E, Arstila M, Timmer C, Lehtonen A. 1988. Bepridil in '
'the elderly. A pharmacokinetic and clinical monitoring study. Curr Ther '
'Res 44:752–758.',
'journal-title': 'Curr Ther Res'},
{ 'key': 'e_1_3_2_64_2',
'doi-asserted-by': 'publisher',
'DOI': '10.2165/00003088-199700321-00004'},
{'key': 'e_1_3_2_65_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s002280000176'},
{'key': 'e_1_3_2_66_2', 'doi-asserted-by': 'publisher', 'DOI': '10.5414/CP201843'},
{ 'key': 'e_1_3_2_67_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S1473-3099(14)70717-0'},
{'key': 'e_1_3_2_68_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cts.12840'}],
'container-title': 'Antimicrobial Agents and Chemotherapy',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.01015-23',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.01015-23',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 4, 3]],
'date-time': '2024-04-03T13:07:38Z',
'timestamp': 1712149658000},
'score': 1,
'resource': {'primary': {'URL': 'https://journals.asm.org/doi/10.1128/aac.01015-23'}},
'subtitle': [],
'editor': [{'given': 'James E.', 'family': 'Leggett', 'sequence': 'additional', 'affiliation': []}],
'short-title': [],
'issued': {'date-parts': [[2024, 4, 3]]},
'references-count': 67,
'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2024, 4, 3]]}},
'alternative-id': ['10.1128/aac.01015-23'],
'URL': 'http://dx.doi.org/10.1128/aac.01015-23',
'relation': {},
'ISSN': ['0066-4804', '1098-6596'],
'subject': ['Infectious Diseases', 'Pharmacology (medical)', 'Pharmacology'],
'container-title-short': 'Antimicrob Agents Chemother',
'published': {'date-parts': [[2024, 4, 3]]},
'assertion': [ { 'value': '2023-08-16',
'order': 0,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-02-20',
'order': 1,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-03-12',
'order': 2,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
